Click on image to view larger version.

Figure 1 Primary end point: death, myocardial infarction, and recurrent ischemia within nine days in patients treated with fondaparinux or enoxaparin (enox) for the intention-to-treat (upper panel) and per-protocol analyses (lower panel). The shaded area of each bar represents the proportion of patients with death or myocardial infarction. Significant differences were only apparent in the per-protocol analysis, as indicated in the figure.